by Usha Govindarajulu | Jul 21, 2021 | Biostatistics, Blog, Healtcare, Professor, Usha Govindarajulu
With all the news about vaccine efficacy and how long the effects of the vaccine will last, it is interesting to wonder how the statistical models to detect such effects are designed for such research . In the Khoury et al paper (2020), they do consider the decay of...
by Usha Govindarajulu | Jul 9, 2021 | Biostatistics, Blog, Epidemiology, Healtcare, Professor, Usha Govindarajulu
Re-analyses on vaccine efficacy in COVID-19 research Much of the news these days focuses on vaccine efficacy rates being re-updated due to various new COVID-19 variants coming out often, originating in different countries, like delta (B.1.167.2) from India and lambda...
by Usha Govindarajulu | Jun 9, 2021 | Biostatistics, Blog, Healtcare, Professor, Usha Govindarajulu
P-values and vaccine efficacy As the companies continue to re-evaluate vaccine efficacy against new variants, have they discussed p-values? Are they analyzing re-updated data again and again and correcting for inflation of the Type I error rate?? Given the...
by Usha Govindarajulu | Feb 17, 2021 | Blog, Epidemiology, Healtcare, New York, Professor, Usha Govindarajulu
Much of the new these days focuses around the vaccines that are out on the market due to emergency authorizations for their use due the continued spread and decimation caused by COVID-19. One of the major concerns that have been raised besides safety are also how the...
by Usha Govindarajulu | Nov 12, 2020 | Blog, Epidemiology, Healtcare, Usha Govindarajulu
The White House has been following a contestable strategy related to controlling the coronavirus called the Great Barrington Declaration. In this declaration created by Jay Bhattacharya, Sunetra Gupta, and Martin Kulldorff, who are all academics, they advocate for...
by Usha Govindarajulu | Oct 29, 2020 | Epidemiology, Healtcare, Usha Govindarajulu
Recently, the FDA deemed Remdesivir as a treatment for COVID-19, the first treatment approved as such. Back on May 1, they had granted EUA, emergency use authorization, of Remdesivir for COVID-19 and many hospitals made use of it, especially given that there was very...
